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GİRİŞ ve AMAÇ: Bu çalışmada pulmoner hipertansiyon (PH) kliniği ile 
karakterize olan preterm ve term infantların, inhale nitrik oksit (iNO) 
tedavisine yanıtlarındaki etkinliğin değerlendirilmesi amaçlanmıştır. 
 
YÖNTEM ve GEREÇLER: Çalışma kohortu 2015-2019 yılları arasında 
iNO tedavisi alan hastalardan oluşmuştur, hastalar gestasyon haftaları ve 
PH tanısının zamanına göre sınıflandırılmıştır. 
 
BULGULAR: Çalışmaya toplamda 56 vaka dahil edilmiştir. iNO öncesi 
ve iNO sonrası ortalama hava yolu basınç değerleri ve oksijenasyon 
indeksi preterm infantların grubunda anlamlı düzeyde yüksek bulundu (p 
< 0.05). Erken PH tanısı alan grupta ortalama gestasyon haftası (GH) ve 
doğum ağırlığı (DA) daha yüksek bulundu. INO tedavisine yanıt veren 
grupta GH'ları ve DA'nın belirgin yüksek oldugu izlendi (p < 0.05). INO 
tedavisine yanıt alınamayan hastaların genellikle tanıları term bebeklerde 
diafragma hernisi iken pretermlerde sepsisdi. 
 
TARTIŞMA ve SONUÇ: Term infantlarda İNO tedavisine daha iyi 
yanıt alınmakla beraber pretermlerde de İNO tedavisine erken başlanması 
ile daha iyi yanıt alınabilir. 
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INTRODUCTION: This study aimed at assessing the data of term and preterm neonates with 
pulmonary hypertension (PH) to characterise patients and the effectiveness of inhaled nitric 
oxide (iNO).   
MATERIALS and METHODS: The study cohort treated with iNO between 2015 and 2019 
was categorized into two groups according to the gestational age (GA) and timing of PH.  
RESULTS: Overall 56 neonates were enrolled. Pre-iNO, post-iNO mean airway pressure 
values, and oxygenation index were significantly higher in the preterm group (p < 0.05). 
Mean GA and birth weight of the infants who had early PH diagnosis were higher. Positive 
responders were more likely to have higher GA as well as higher birth weight (p < 0.05). 
Non-responders were mostly diagnosed with diaphragmatic hernia in term infants and with 
sepsis in preterm infants 
CONCLUSIONS: Despite term infants have higher positive response rate to treatment, 
initiating early treatment will increase the rate of positive response in preterm infants. 

















Nitric oxide (NO) molecule was found out 30 years ago and shortly after the discovery of NO, 
known as endothelial-derived relaxing factor, studies showed that it is a pulmonary-specific 
vasodilator (1). NO administered via inhalation (iNO) is a fat soluble, unstable, free radical 
gas. It is a small molecule that can be easily transferred through cell membranes; its half life 
is short and is expressed in seconds (2). Endogenous NO synthesis in neonates is induced by 
various events such as birth, stress, oxygen increase, or sepsis and formed via nitric oxide 
synthase, and it causes vasodilatation in smooth muscle cells via cGMP. iNO provides 
selective vasodilation in the pulmonary veins with its selective effect characteristic, and it also 
increases blood flow in the alveoli by decreasing the ventilation perfusion mismatch with its 
micro-selective effect (3). 
The use of iNO improves oxygenation in neonates with persistent pulmonary hypertension 
(PH) (4). Persistent PH arises in neonates either as a primary or secondary condition to 
respiratory distress syndrome, meconium aspiration, sepsis, or birth asphyxia. (5-7). It is 
characterized by persistently increased pulmonary vascular resistance and arterial pressure 
that is associated with extrapulmonary right-to-left shunting leading to hypoxemic respiratory 
failure in tertiary neonatal intensive care units (NICUs). iNO is an effective but costly therapy 
which was approved for only late preterm and term infants with PH; however, off-label use of 
iNO has become widespread as 5%–7% cases in preterm infants. (8, 9). In term and preterm 
infants, iNO is used to treat PH caused by various reasons (10). Cochrane review reported that 
iNO use improves oxygenation in term and late preterm infants, whereas it does not have an 
effect on mortality and length of hospital stay and is also ineffective in smaller preterm 
infants (11, 12). 
The primary objective of this study is to characterize the term and preterm cases in whom we 
used iNO for 4 years in the neonatal intensive care unit. The secondary objective is to identify 
factors associated with improved outcomes and favourable response to iNO therapy and to 
evaluate our iNO practice. 
 




MATERIALS and METHODS 
A retrospective-cohort study was conducted at the University of Health Sciences, Bursa 
Yuksek Ihtisas Teaching Hospital between 2015 and 2019 after approval of the study by the 
local ethics committee. We included term and preterm infants treated with iNO in our NICU. 
Infants who had major congenital cardiac as well as other major anomalies were excluded. 
The infants were categorized into two groups: Group 1, gestation age (GA) <34 weeks and 
Group 2, GA ≥34 weeks. iNO treatment was initiated under inadequate oxygen supply 
conditions with conventional mechanical ventilation strategies or severe respiratory failure 
[mean airway pressure (MAP) of ≥10 or oxygenation index of ≥25]. Oxygenation index (OI) 
was calculated as (MAP [cm H2O] × fraction of inspired oxygen [FIO2] × 100)/partial 
pressure of oxygen in arterial blood (PaO2) (mmHg). Measured oxygen saturation difference 
between the pre-ductal and post-ductal points in all infants was above 10%. 
Echocardiography (ECHO) was performed in some patients to measure PH and make a 
definite diagnosis and exclude the diagnosis of congenital heart diseases. iNO treatment was 
continuously administered intratracheally during mechanical ventilation. The treatment was 
started at a dose of 20 ppm, and patients who had FiO2 reduced to ≥0.20 during the 1
st
 hour of 
treatment were considered as positive responders. In positive responders, the treatment was 
kept at 20 ppm until OI reached <10 and FiO2 reached <60; thereafter, weaning was 
decreasing every 4 to 6 hours. After 1 hour, if FiO2 level did not change or decreased to <0.10 
despite the treatment, the treatment was terminated according to the protocol. The patients 
were classified into two groups according to the initiation time of iNO treatment as early 
(iNO initiation at ≤3 days of age) or late (at >3 days of age). 
The following data were recorded: maternal medical history, prenatal demographics, antenatal 





min, diagnoses, hospital stay durations, and mortality data. In addition, data related to iNO 
use; initiation time, treatment responses, treatment duration and MAP before (pre-iNO) and 2 
hours after (post-iNO), FiO2, and OI were recorded. Based on these values, intra- and inter-
group comparisons were performed to determine the “iNO responder” group.  




Statistical analyses: Statistical analyses of the data were performed using the Statistical 
Package for the Social Sciences (SPSS) version 20.0 software (SPSS Inc., Chicago, IL, USA). 
All the continuous values were presented as the median (interquartile range, IQR) and mean ± 
standard deviation, where suitable. The categorical values were presented as the frequency 
and percentage. Chi-square analysis and Fisher’s exact test was used for comparing 
categorical variables among the groups. Student’s t-test was used for continuous variables and 
Mann–Whitney U was used for comparing nonparametric variables. Binary logistic regression 
(forward logistic regression) was used in the multivariate analysis to determine the factors 
associated with positive responders. Variables included in the analyses were gestational age, 
birth weight, sex, early PHT, PHT-definite, pre-iNO MAP, pre-iNO oxygenation index, 
duration of ventilation and oxygen treatment days, length of hospital stay and mortality. 




Overall 56 neonates received iNO at the NICU during the 4-year study. After excluding 
infants meeting the exclusion criteria, 44 neonates were included in the final analysis. A total 
of 33 (75%) cases were classified as definite PH based on echocardiography results. Of the 
analysed patients, 32 (72%) were in the early PH group, whereas 12 (28%) were in the late 
PH group. Although mean gestational age and birth weight of the infants diagnosed with early 
PH were higher, no significant difference was observed. Clinical diagnoses of early and late 








Table 1: Neonatal and maternal characteristics of early and late pulmonary hypertension groups 






GA at birth, wk 
median (IQR) 










Sex, n (%) 











Apgar score, median (IQR) 
   Minute 1 













Antenatal steroid, n (%) 6 (19) 3(25)  0.8
c 
Maternal risk factors 
   Hypertension 
  Gestational diabetes 
  Abruptio plasenta 
  PPROM                                                                                                                                                     
 
























 MAS                                                               
Sepsis 


























a Mann-Whitney U test, b Student t test, , c Chi Square test 
PH: pulmonary hypertension; GA: gestational age; wk: week; IQR: interquartile range; BW: birth weight; g: gram; C/S: 
cesarean section; PPROM: preterm prolonged rupture of membranes; MAS: Meconium aspiration syndrome HIE: hypoxic 
ischemic encephalopathy, RDS: Respiratory distress syndrome, BPD: bronchopulmonary dysplasia; TTN: Transient 
Tachypnea of the Newborn 
 
 
After the infants were classified according to birth weeks, 17 (39%) were at <34 gestation 
weeks (group 1) and 27 (61%) were at >34 gestation weeks (group 2). After comparing these 
groups, pre-iNO, post-iNO, MAP, pre-iNO, and OI values were found to be significantly 
higher in group 1. Age at PH was significantly different with averages being at the third day 
in Group 1 and first day in Group 2 (p = 0.04). As we expected, length of stay was longer in 
Group 1 (p = 0.03). Furthermore, iNO response was better among infants with higher 
gestational age (p = 0.04). Clinical and laboratory findings of the groups are presented in 
Table 2. 




Table 2: Clinical and laboratory findings of the groups 




























Duration of 02 treatment 
(days) 









Age at PH (days) 
 














Duration of iNO use (hours)      84 ± 40 
 




HFO at ino  
 







Pre-iNO mean airway pressure 
(cmH2O) 






















Post-iNO mean airway 
pressure (cmH2O) 
13 ± 1 
 












Post-iNO OI 25 ± 6 
 


















≥ Grade 3 intraventricular 
haemorrhage 




























aChi Square test, , bMann-Whitney U test, cStudent-T test. PH: pulmonary hypertension, iNO: inhaled nitric oxide, HFO: 
high frequency ventilation, FiO2: fraction of inspired oxygen, OI: oxygenation index 




When the infants born with gestational age before 34 weeks were compared according to the 
iNO initiation day, duration of ventilation days, and O2 treatment days were significantly less 
(p = 0.004 and p = 0.02 respectively) in the early PH group. In early PH group, nine (90%) 
cases were classified as definite PH based on echocardiography results and only one (10%) 
from the documented pre-iNO pre–post ductal saturation difference (p = 0.02). Although there 
was no statistical significance, positive response rate was higher in the early PH group [5/10 
(50%) vs. 2/8 (25%)]. Mortality was less in the early PH group compared to the late PH group 
(Table 3). 
 
Table 3: Clinical and laboratory findings of the preterm infants  
 
 Early PH (n=10)  
 
 













Duration of ventilation 
 (days) 
  
         13 ± 10 
 






Duration of 02 treatment 
(days) 
23 ± 20  
 






















Duration of iNO use (hours) 75 ± 42 
 









Pre-iNO mean airway pressure 
(cmH2O) 
13 ± 2 
 













Pre iNO OI 33 ± 6  32 ± 7   0.8
b
 
Post-iNO mean airway 
pressure (cmH2O) 
13 ± 1 
 






Post-iNO FiO2 0.8 ± 0.1 
 

































İNO responsiveness 5 (50)  2 (25)   0.3
a
 
Mortalite 2 (20)  4 (50)   0.2
a
 
aChi Square test, , bStudent-T test, cMann-Whitney U test, PH: pulmonary hypertension, iNO: inhaled nitric oxide, HFO: 
high frequency ventilation, FiO2: fraction of inspired oxygen, OI: oxygenation index 





When all patients were evaluated, positive response rate to iNO treatment was 57%, whereas 
in term infants, positive response rate was 70%. Positive responders were more likely to be 
with higher GA and higher birth weight (Table 4).  
Table 4: Comparision of baseline characteristics of positive responders  








GA at birth, wk 
median (IQR) 











2525 ± 790  
 







Sex, n (%) 
 Male 



























        0,3
a
 







































aMann-Whitney U test, bStudent-T test, cChi Square test GA: gestational age; wk: week; IQR: interquartile range; BW: 
birth weight; g: gram; PH: pulmonary hypertension, iNO: inhaled nitric oxide, OI: oxygenation index;  
 
According to forward binary logistic regression results, only GA and birth weight were 
significant factors for positive responders. GA was significant risk factor with odds ratio [OR] 
= 1.869 [95% confidence interval (CI): 1.204–2.901; p = 0.005], whereas birth weight was 
preventive factor with OR = 0.998 (CI: 0.996–0.999; p = 0.036) for positive responders. 
When the clinical diagnoses of patients who did not respond to iNO treatment were examined, 
it was observed that the non-responders ‘rate was the highest in the diaphragmatic hernia (4/8) 
group in term infants and in sepsis (4/11) group in preterm infants. 





Inhaled NO therapy effectively improves oxygenation in term infants with hypoxic 
respiratory failure and persistent PH (4, 13). However, the indication for iNO therapy is not 
well defined in preterm infants. Furthermore, the characteristics and diagnoses of infants 
responding to iNO treatment are not clear. In this study, we aimed to identify our iNO 
experience in term and preterm infants admitting at our neonatal intensive care unit 
throughout 4 years, the characteristics of our patient groups, and the factors associated with 
favourable response to iNO therapy. 
The neonatal pulmonary vascular system is generally unstable. The maturation of endothelial 
cell function, release of vasoactive mediators, vascular wall remodelling, and smooth muscle 
cell differentiation are involved in the maturation process (14). Neonatal PH is caused by a 
variety of factors including maternal anemia, fever, lung disease, diabetes mellitus, 
meconium- stained amniotic fluid, perinatal asphyxia, fetal distress, and sepsis (15). iNO is a 
selective pulmonary vasodilator and is used for treating early persistent PH in term infants. In 
preterm infants, it is especially used in respiratory failure, respiratory distress syndrome 
(RDS), or bronchopulmonary dysplasia (BPD) that does not respond to conventional 
treatments (16). In our study, GA and birth weight of the neonates in early PH group were 
higher than the late PH group. The most frequent diagnosis in the early PH cohort was 
diaphragmatic hernia, whereas the most frequent in the late PH cohort was BPD. 
The National Institutes of Health consensus panel and the American Academy of Pediatrics 
Committee on Fetus and Newborn has reported that there is no sufficient evidence to 
recommend the routine use of iNO in preterm infants with GA <34 weeks (17, 18). However, 
in the guideline published by the American Heart Association and the American Thoracic 
Society, it was reported that iNO therapy can be beneficial especially for EMR and 
oligohydramnios infants with PH secondary to hypoxemia in preterm (19). In the recent years, 
there have been studies showing that iNO use is effective in preterm infants at least as much 
as in term infants (20). Due to these conflicting reports, we evaluated our own patient group. 
Majority of our patient group was formed by infants with GA >34 weeks. Early PH diagnosis 
was apparently defined more for infants with GA >34 weeks. This was most probably caused 
by the diagnoses of the patients in this group with hypoxic ischemic encephalopathy and 
diaphragmatic hernia encountered with early PH clinic. As expected, received surfactant rate, 




duration of ventilation days, length of hospital stays and iNO responsiveness of the group 
with GA <34 weeks were higher. When the OI and MAP values of the groups before and after 
iNO were compared, it was observed that pre-iNO MAP and OI values were higher in the 
infants with GA <34 weeks. This made us consider that we may have been late in starting the 
iNO treatment in preterm infants which decreased our iNO treatment success in preterm 
infants. In a recently published study, it was shown that patients between OI 15–25 have 
better clinically significant improvements and mortality compared to the OI of >25 group 
(21). Further studies are needed with large case series comprising various OI groups to prove 
this hypothesis. 
In preterm infants, unlike term neonates, we observed pulmonary diseases to be a secondary 
particularly to RDS. The prevalence of RDS causing oxygenation failure has now decreased 
after antenatal steroids and postnatal surfactant therapy (22). In preterm infants, other than 
RDS, sepsis, persistent fetal circulation, or BPD can damage the pulmonary vascular structure 
which may clinically encountered PH. (10). In animal studies, it was shown that NO synthase 
expression decreases in the epithelium of small airways as well as in the endothelium of the 
distal pulmonary artery in chronic pulmonary disease (23). At the same time tracheal aspirate 
analysis in hypoxemic PH preterm infants with PPROM or sepsis has shown a transient defect 
in endogenous nitric oxide generation (22). In our study, RDS along with PH secondary to 
sepsis in the early period and PH associated with BPD in the late period were detected in the 
preterm infants. In compliance with the literature, PPROM and oligohydramnios prevalence 
were higher in the preterm group due to the need for iNO. Due to this treatment is off-label in 
preterm infants with GA <34 weeks, there are very few studies concerning this area (6,10,16). 
In our study, early PH group with GA <34 weeks were monitored with less oxygen treatment 
and ventilation days and definite-PH diagnoses were more. This was caused by the late PH 
group consisting mostly of the BPD diagnosis and these being started with the treatment 
without the need for definite diagnosis with ECHO. 
iNO response in PH treatment is associated with gestational age in neonates. Cochrane meta-
analysis states that iNO therapy in term and near-term infants, OI decreased by a mean of 15.1 
within 30–60 min after the start of therapy (12). However, Cochrane meta-analysis states that 
in preterm infants, early routine use of iNO did not appear to be effective but later use of iNO 
to prevent BPD could be effective (11). In our study, the positive response rate to iNO 
treatment was 57% in patients who received iNO and 70% for term infants. The evaluation of 
factors associated with iNO responsiveness according to forward binary logistic regression 




analysis showed that only GA and birth weight were significant factors for positive 
responders. GA was significant risk factor, whereas birth weight was preventive factor for 
positive responders. Moreover, preliminary OI values and mortality rates in the iNO 
responder group were lower. When the clinical diagnoses of the patients who were non-
responders to the iNO treatment were evaluated, it was observed as consistent with the 
literature that the worst responses were in the diaphragmatic hernia group in term infants and 
the sepsis group in the preterm infants. 
There are limitations of this study where first one is its retrospective design; however, we 
were able to use a highly reliable neonatal database that identified all the infants with PH. As 
a second one, we did not have a control group of untreated infants, so we cannot confirm the 
impact of iNO on neonatal outcomes. In addition, we could not determine subgroups of 
different pre-iNO OI and MAP values which is the third limitation. As a final one, our sample 
size was relatively small due to iNO use which is limited in the NICU and even less in 
preterm infants. Despite these limitations, there are powerful strengths of our study that are an 
important addition to the limited clinical study data available in preterm infants with PH and 
provide valuable insight into the actual use of iNO.  
Conclusion: In conclusion, iNO is used for treating neonatal PH in term and preterm infants. 
As it is an off-label treatment in preterm infants, the parameters for iNO treatment initiation 
decision are quite high. This can decrease iNO treatment success in neonates in critical 
condition who would not have the chance to be given ECMO, such as preterm infants. Thus, 
iNO use should be optimized in preterm infants. Therefore, there is a need for large case 
series studies with subgroups of various diagnoses and pre-iNO parameters. 
Conflict of Interest: No potential conflict of interest was reported by the authors.  
 










1.Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial 
smooth muscle by acetylcholine. Nature. 1980;288(5789):373-6. 
2.Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a 
cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 
1991;338(8776):1173-4. 
3.Sokol GM, Konduri GG, Van Meurs KP. Inhaled nitric oxide therapy for pulmonary disorders of the 
term and preterm infant. Semin Perinatol. 2016;40(6):356-69. 
4.Roberts JD, Jr., Fineman JR, Morin FC, 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric 
oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. 
N Engl J Med. 1997;336(9):605-10. 
5.Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin 
Perinatol. 2005;29(1):8-14. 
6.Dani C, Corsini I, Cangemi J, Vangi V, Pratesi S. Nitric oxide for the treatment of preterm infants 
with severe RDS and pulmonary hypertension. Pediatr Pulmonol. 2017;52(11):1461-8. 
7.Chandrasekharan P, Kozielski R, Kumar VH, Rawat M, Manja V, Ma C, et al. Early Use of Inhaled 
Nitric Oxide in Preterm Infants: Is there a Rationale for Selective Approach? Am J Perinatol. 
2017;34(5):428-40. 
8.Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide 
after release of NIH consensus statement. Pediatrics. 2015;135(4):643-8. 
9.Soraisham AS, Harabor A, Shivananda S, Alvaro R, Ye XY, Lee SK, et al. Trends and Variations in 
the Use of Inhaled Nitric Oxide in Preterm Infants in Canadian Neonatal Intensive Care Units. Am J 
Perinatol. 2016;33(7):715-22. 
10. Baczynski M, Ginty S, Weisz DE, McNamara PJ, Kelly E, Shah P, et al. Short-term and long-term 
outcomes of preterm neonates with acute severe pulmonary hypertension following rescue treatment 
with inhaled nitric oxide. Arch Dis Child Fetal Neonatal Ed. 2017;102(6):F508-F14. 
11.Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. 
Cochrane Database Syst Rev. 2017;1:CD000509. 
12.Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at 
or near term. Cochrane Database Syst Rev. 2017;1:CD000399. 




13.Neonatal Inhaled Nitric Oxide Study G. Inhaled nitric oxide in full-term and nearly full-term 
infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597-604. 
14.Sood BG, Wykes S, Landa M, De Jesus L, Rabah R. Expression of eNOS in the lungs of neonates 
with pulmonary hypertension. Exp Mol Pathol. 2011;90(1):9-12. 
15.Simpson CM, Smolich JJ, Shekerdemian LS, Penny DJ. Urotensin-II contributes to pulmonary 
vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary 
to meconium aspiration syndrome. Pediatr Res. 2010;67(2):150-7. 
16.Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, et al; NICHD 
Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, 
oligohydramnios, and pulmonary hypoplasia. Am J Perinatol. 2009;26(4):317-22. 
17. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, et al.  NIH Consensus 
Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics. 
2011;127(2):363-9. 
18.Kumar P, Committee on F, Newborn, American Academy of P. Use of inhaled nitric oxide in 
preterm infants. Pediatrics. 2014;133(1):164-70. 
19.Abman SH, Ivy DD, Archer SL, Wilson K, Committee AAJGfPPH. Executive Summary of the 
American Heart Association and American Thoracic Society Joint Guidelines for Pediatric Pulmonary 
Hypertension. Am J Respir Crit Care Med. 2016;194(7):898-906. 
20.Suzuki S, Togari H, Potenziano JL, Schreiber MD. Efficacy of inhaled nitric oxide in neonates with 
hypoxic respiratory failure and pulmonary hypertension: the Japanese experience. J Perinat Med. 
2018;46(6):657-63. 
21.Rhine WD, Suzuki S, Potenziano JL, Escalante S, Togari H. An Analysis of Time to Improvement 
in Oxygenation in Japanese Preterm and Late Preterm or Term Neonates With Hypoxic Respiratory 
Failure and Pulmonary Hypertension. Clin Ther. 2019;41(5):910-9. 
22.Aikio O, Metsola J, Vuolteenaho R, Perhomaa M, Hallman M. Transient defect in nitric oxide 
generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm 
infants with hypoxic respiratory failure. J Pediatr. 2012;161(3):397-403 e1. 
23.MacRitchie AN, Albertine KH, Sun J, Lei PS, Jensen SC, Freestone AA, et al. Reduced endothelial 
nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am J Physiol Lung Cell Mol 
Physiol. 2001;281(4):L1011-20. 
 
